Overview
68Ga-P3 PET/CT Imaging in Malignancy
Status:
Recruiting
Recruiting
Trial end date:
2025-07-31
2025-07-31
Target enrollment:
0
0
Participant gender:
All
All
Summary
Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein that consists of 750 amino acids. It is highly expressed on most prostate cancer cells and neovascular endothelial cells of tumors, making PSMA a highly specific and significant imaging target for malignancies. [68Ga]P3, a novel molecular probe of PET imaging agent that targets PSMA, can be used in the diagnosis and research of a wide variety of PSMA high-expression malignanciesr.Phase:
N/AAccepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Peking University First Hospital
Criteria
Inclusion Criteria:patients with confirmed or suspected cancer; 18F-FDG PET/CT within 1 week; Signed written
informed consent
Exclusion Criteria:
Pregnant and lactating women; Female patients plan to become pregnant within 6 months.